Abstract
Respiratory infections that result in severe and life-threatening immune-mediated respiratory decline are a major public health issue. Controlling local respiratory immune reactions without the use of systemic immunosuppressants remains an unmet clinical challenge. We developed a gene delivery system to express anti-inflammatory cytokines in the lung, which reestablishes local immune homeostasis without triggering systemic effects. Using an adeno-associated vector cargo system (AAV6.2- CC10 ), we induced production of interleukin-2 (IL-2), IL-1 receptor antagonist (IL-1RA), and IL-10 in situ in the lung microenvironment, with no detectable expression or immunological deviation in the peripheral immune system. We demonstrate the effective potential of IL-2, IL-1RA, and IL-10 as immunomodulatory cargos in severe infectious challenge, which reduced respiratory pathology after influenza-associated pulmonary aspergillosis. Thus, the AAV6.2- CC10 platform enables targeted delivery of biologics to the lung, modulates the lung environment, and improves pathology without inducing systemic immune reactions.
Funding Information
  • Wellcome Trust (222442/A/21/Z)
  • Wellcome Trust (227236/Z/23/Z)
  • H2020 European Research Council (MSCA-IF REP-893236-1)
  • Fonds Wetenschappelijk Onderzoek (1199825N)
  • Gates Cambridge Trust (OPP1144)
  • Wallonie-Bruxelles International (SUB/2021/513056)
  • Vlaamse regering (G053121N)
  • Vlaamse regering (1186121N/1186123)
  • Vlaamse regering (PDMT2/24/075)
  • Junior Postdoctoral Mandate (1266926N)

This publication has 77 references indexed in Scilit: